购物车
您的购物车当前为空
别名 Catadegbrutinib, BTK 抑制剂-29, BGB-16673
BTK-IN-29是一种选择性和口服活性的BTK降解剂(IC50=0.69 nM),能够降解整个BTK蛋白和对抗BTK突变,可用于研究B细胞恶性肿瘤,如慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、套细胞淋巴瘤等。


为众多的药物研发团队赋能,
让新药发现更简单!
BTK-IN-29是一种选择性和口服活性的BTK降解剂(IC50=0.69 nM),能够降解整个BTK蛋白和对抗BTK突变,可用于研究B细胞恶性肿瘤,如慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、套细胞淋巴瘤等。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 413 | 现货 | |
| 5 mg | ¥ 787 | 现货 | |
| 10 mg | ¥ 1,260 | 现货 | |
| 25 mg | ¥ 1,980 | 现货 | |
| 50 mg | ¥ 3,380 | 现货 | |
| 100 mg | ¥ 4,830 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,170 | 现货 |
| 产品描述 | BTK-IN-29 is a selective, orally active BTK degrader (IC50=0.69 nM) capable of degrading the entire BTK protein and counteracting BTK mutations. It can be used to study B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and others. |
| 靶点活性 | BTK:0.69 nM |
| 体内活性 | 对于皮下植入REC-1癌细胞的NCG小鼠,BGB-16673 (BTK-IN-29)(6/20 mg/kg)剂量依赖性地和有效地抑制肿瘤生长[3]。 |
| 别名 | Catadegbrutinib, BTK 抑制剂-29, BGB-16673 |
| 分子量 | 851.01 |
| 分子式 | C47H54N12O4 |
| CAS No. | 2736508-60-2 |
| Smiles | CC=1C=C(C2=C3C(NC(=C3)C=4C=CC(=NC4)N5CCN(CC6CCN(CC6)C7=CC=C(C=C7)N8C(=O)NC(=O)CC8)CC5)=NC=N2)C=CC1[C@H](NC(=O)C9=NC(C(C)(C)C)=NO9)C |
| 存储 | keep away from direct sunlight | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (117.51 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多